Share Twitter LinkedIn Facebook Email Sara M. Tolaney, MD, MPH, talks about the TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene recurrence score patients, means endocrine therapy alone is similar in efficacy to chemoendocrine therapy
Strategizing Personalized Breast Cancer Treatment: A Promising Overview of Advances and Clinical Applications [39 SLIDES] Breast 4 Mins Read
Fertility Preservation: Interrupting endocrine therapy to attempt pregnancy in Breast Cancer Breast 2 Mins Read